{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Epigenetics > JQ1CAS：1268524-70-4
Molecular Formula：C23H25ClN4O2S
Molecular Weight：456.99
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to yellow Solid
Qty：
Size：
| CAS | 1268524-70-4 |
| Name | JQ1 |
| Molecular Formula | C23H25ClN4O2S |
| Molecular Weight | 456.99 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | White to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD22683748 |
| SMILES | O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C |
| InChIKey | DNVXATUJJDPFDM-KRWDZBQOSA-N |
| InChI | InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1 |
| PubChem CID | 46907787 |
| Target Point | Epigenetic Reader Domain |
| Passage | Epigenetics |
| Background | (+)-JQ-1 is a BET bromodomain inhibitor. |
| Biological Activity | (+) -JQ-1 是一种 BET bromodomain 抑制剂, 抑制 BRD4 (1/2) 的 IC50 分别为 77 nM 和 33 nM[1]。 |
| IC50 | IC50: 77/33nM (BRD4(1/2) ) [1] |
| Data Literature Source | [1]. Filippakopoulos P， et al. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23; 468 (7327) :1067-73. [2]. Matzuk MM， et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012 Aug 17; 150 (4) :673-84. [3]. Peirs S， et al. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia. 2017 Feb 3. [4]. T gel L， et al. Dual Targeting of Bromodomain and Extraterminal Domain Proteins， and WNT or MAPK Signaling， Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Mol Cancer Ther. 2016 Jun; 15 (6) :1217-26. [5]. Sahni JM， et al. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. J Biol Chem. 2016 Nov 4; 291 (45) :23756-23768. [6]. Nakamura Y， et al. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. Cancer Lett. 2017 Aug 28; 402:100-109. [7]. Bhattacharyya S， et al. Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Genome Res. 2017 Nov; 27 (11) :1830-1842. [8]. Lv B， et al. Enhancement of adenovirus infection and adenoviral vector-mediated gene delivery by bromodomain inhibitor JQ1. Sci Rep. 2018 Aug 1; 8 (1) :11554. doi: 10.1038/s41598-018-28421-x. [9]. Huang X， et al. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Cell. 2018 Sep 20; 175 (1) :186-199.e19. doi: 10.1016/j.cell.2018.08.058. Epub 2018 Sep 13. |
| Unit | Piece |
| Specification | 5mg 10mg 25mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
